BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| BCRX | BIOCRYST PHARMACEUTICALS INC | 2026-10-15 14:34:25 | 8.07 | 0.02 | 0.19 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BCRX | 0000882796 | BIOCRYST PHARMACEUTICALS INC | US09058V1035 | 549300Z0INP1Z5NP6J59 | 621413174 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 4505 EMPEROR BOULEVARD | DURHAM | NC | 27703 | UNITED STATES | US | 919-859-1302 | 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703 | 4505 EMPEROR BOULEVARD, DURHAM, NC, 27703 | — | Healthcare | 1986 | Charlie Gayer | 450 | https://www.biocryst.com/ | 1,863,392,680 | 255,265,000 | 255,535,105 | BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020. | 2026-10-09 02:21:32 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 1,863,392,680 | 598,742,163 | 47.3445 | 250,800,620 | 41,840,600 | 20.0233 |
| 2024 | 1,264,650,517 | -58,250,280 | -4.4032 | 208,960,020 | 2,810,091 | 1.3631 |
| 2023 | 1,322,900,797 | -626,383,806 | -32.134 | 206,149,929 | 17,698,792 | 9.3917 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 2025 | 271,515 | 160,000 | 2,124,571 | 506,400 | 10,500 | 6,748,152 |
| Alane P. Barnes | Chief Legal Officer, Corporate Secretary | 2025 | 542,519 | 0 | 867,721 | 553,369 | 17,500 | 5,616,032 |
| Jon P. Stonehouse | Chief Executive Officer, President | 2025 | 728,466 | 0 | 0 | 1,052,633 | 37,525 | 12,951,082 |
| Anthony J. Doyle | Chief Financial Officer, Treasurer | 2025 | 151,925 | 0 | 708,694 | 0 | 114,700 | 2,141,135 |
| Charles K. Gayer | Chief Executive Officer, President, Chief Commercial Officer | 2025 | 609,397 | 0 | 3,358,230 | 749,088 | 17,500 | 9,627,868 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 435 |
| 2024 | 580 |
| 2023 | 536 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 874,837,000 | 450,712,000 | 331,412,000 |
| Cost Of Revenue | 19,075,000 | 12,269,000 | 4,481,000 |
| Gross Profit | 855,762,000 | 438,443,000 | 326,931,000 |
| Research And Development Expenses | 166,126,000 | 174,638,000 | 216,566,000 |
| General And Administrative Expenses | 348,647,000 | 266,132,000 | 213,894,000 |
| Operating Expenses | 533,848,000 | 453,255,000 | 435,121,000 |
| Operating Income | 340,989,000 | -2,543,000 | -103,709,000 |
| Net Income | 263,861,000 | -88,881,000 | -226,539,000 |
| Earnings Per Share Basic | 1.26 | -0.43 | -1.18 |
| Earnings Per Share Diluted | 1.21 | -0.43 | -1.18 |
| Weighted Average Shares Outstanding Basic | 209,893,000 | 206,696,000 | 192,198,000 |
| Weighted Average Shares Outstanding Diluted | 218,581,000 | 206,696,000 | 192,198,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 89,736,000 | 104,713,000 | 110,643,000 |
| Marketable Securities Current | 185,011,000 | 216,137,000 | 278,344,000 |
| Accounts Receivable | 106,818,000 | 79,069,000 | 2,296,000 |
| Inventories | 5,398,000 | 31,274,000 | 28,683,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 17,182,000 | 13,752,000 | 19,542,000 |
| Total Assets Current | 404,346,000 | 421,968,000 | 495,966,000 |
| Marketable Securities Non Current | 61,164,000 | 20,323,000 | 0 |
| Property Plant And Equipment | 8,783,000 | 7,777,000 | 7,910,000 |
| Other Assets Non Current | 5,672,000 | 5,157,000 | 13,084,000 |
| Total Assets Non Current | 109,812,000 | 68,452,000 | 20,994,000 |
| Total Assets | 514,158,000 | 490,420,000 | 516,960,000 |
| Accounts Payable | 15,826,000 | 11,644,000 | 20,893,000 |
| Deferred Revenue | — | — | 0 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 126,413,000 | 113,292,000 | 102,882,000 |
| Total Liabilities Current | 196,066,000 | 160,384,000 | 149,988,000 |
| Long Term Debt | 0 | 314,869,000 | 303,231,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 437,245,000 | 805,970,000 | 822,500,000 |
| Total Liabilities | 633,311,000 | 966,354,000 | 972,488,000 |
| Common Stock | 2,131,000 | 2,085,000 | 2,058,000 |
| Retained Earnings | -1,506,179,000 | -1,770,040,000 | -1,681,159,000 |
| Accumulated Other Comprehensive Income | 38,000 | 921,000 | 1,337,000 |
| Total Shareholders Equity | -119,153,000 | -475,934,000 | -455,528,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,389,000 | 1,246,000 | 1,655,000 |
| Share Based Compensation Expense | 85,066,000 | 65,413,000 | 55,615,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 36,806,000 | 22,698,000 | 6,095,000 |
| Change In Inventories | 1,639,000 | 4,164,000 | 1,450,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 7,827,000 | -1,959,000 | 6,820,000 |
| Change In Accounts Payable | 57,802,000 | -62,379,000 | -16,806,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 347,369,000 | -52,020,000 | -95,141,000 |
| Purchases Of Marketable Securities | 262,240,000 | 266,763,000 | 514,407,000 |
| Sales Of Marketable Securities | 256,647,000 | 320,480,000 | 385,077,000 |
| Acquisition Of Property Plant And Equipment | 2,468,000 | 1,124,000 | 2,168,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -13,694,000 | 52,593,000 | -131,498,000 |
| Tax Withholding For Share Based Compensation | 8,847,000 | 7,535,000 | 2,172,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 7,879,000 | 2,280,000 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 0 | 0 | 300,000,000 |
| Repayment Of Long Term Debt | 300,000,000 | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -349,931,000 | -5,761,000 | 32,485,000 |
| Change In Cash | -14,986,000 | -6,124,000 | -193,792,000 |
| Cash At End Of Period | 89,736,000 | 104,713,000 | 110,643,000 |
| Income Taxes Paid | 2,803,000 | 1,603,000 | 1,434,000 |
| Interest Paid | 23,735,000 | 30,383,000 | 22,139,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 1.26 | -0.43 | -1.18 |
| Price To Earnings Ratio | 6.1905 | -17.4884 | -5.0763 |
| Earnings Growth Rate | -393.0233 | -63.5593 | -11.2782 |
| Price Earnings To Growth Ratio | -0.0158 | 0.2752 | 0.4501 |
| Book Value Per Share | -0.5677 | -2.3026 | -2.3701 |
| Price To Book Ratio | -13.74 | -3.2659 | -2.5273 |
| Ebitda | 346,925,000 | 12,484,000 | -115,211,000 |
| Enterprise Value | 1,547,429,400 | 1,764,509,920 | 1,343,854,020 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0 | -0.6616 | -0.6657 |
| Capital Expenditures | 2,395,000 | 1,113,000 | 948,000 |
| Free Cash Flow | 344,974,000 | -53,133,000 | -96,089,000 |
| Return On Equity | -2.2145 | 0.1868 | 0.4973 |
| One Year Beta | 0.7853 | 1.3921 | 0.8787 |
| Three Year Beta | 0.9367 | 1.2354 | 1.2965 |
| Five Year Beta | 1.1724 | 1.2665 | 1.2799 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Frank Steven | Director | 2026-08-31 | 1,288 | A | 36,747 |
| McKee Amy E | Director | 2026-08-31 | 644 | A | 47,821 |
| MILANO VINCENT | Director | 2026-08-31 | 1,159 | A | 109,642 |
| Milne Jill C. | Director | 2026-08-31 | 1,288 | A | 33,226 |
| Stonehouse Jon P | Director | 2026-08-31 | 644 | A | 1,340,419 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Gilbert Cisneros | 2026-09-04 | CA31 | Purchase | 2026-07-10 | — | $1,001 - $15,000 |
| Gilbert Cisneros | 2025-12-15 | CA31 | Purchase | 2025-11-13 | — | $1,001 - $15,000 |
| Josh Gottheimer | 2023-11-11 | NJ05 | Purchase | 2023-10-16 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2023-10-15 | NJ05 | Sale | 2023-09-15 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2022-09-16 | NJ05 | Purchase | 2022-08-11 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Activest Wealth Management | 2026-09-30 | 16,660 | 2,000 | 8.33 |
| Assenagon Asset Management S.A. | 2026-09-30 | 3,740,853 | 449,082 | 8.33 |
| Atria Investments, Inc | 2026-09-30 | 101,068 | 12,133 | 8.33 |
| Essential Partners LLC | 2026-09-30 | 6,906 | 829 | 8.3305 |
| Farmers & Merchants Trust Co of Chambersburg PA | 2026-09-30 | 4,000 | 500 | 8 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Pacer Funds Trust | 2026-07-31 | Pacer WealthShield ETF | PWS | 4,436 | 39,835.28 | 0.1655 |
| ETFis Series Trust I | 2026-07-31 | Virtus Biotech ETF | BBP | 155,993 | 1,400,817.14 | 1.4215 |
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 24,911 | 223,700.78 | 0.0276 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 206,445 | 1,853,876.1 | 0.0671 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 111,471 | 1,001,009.58 | 0.0672 |